Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine

AIDS

Volumn 12, Issue 2, 1998, Pages 167-173

  Notermans, Daan W ^a,b   Jurriaans, Suzanne ^b   De Wolf, Frank ^b   Foudraine, Norbert A ^c   De Jong, Jacques J ^b   Cavert, Winston ^d   Schuwirth, Caspar M ^b   Kauffmann, Robert H ^e   Meenhorst, Pieter L ^f   McDade, Hugh ^g   Goodwin, Carolyn ^g   Leonard, John M ^h   Goudsmit, Jaap ^b   Danner, Sven A ^a  

^a Natl AIDS Therapy Evaluation Centre   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MUNICIPAL HEALTH SERVICE   (Netherlands)

^d UNIVERSITY OF MINNESOTA   (United States)

^e LEYENBURG HOSPITAL   (Netherlands)

^f SLOTERVAART HOSPITAL   (Netherlands)

^g GLAXOSMITHKLINE   (United Kingdom)

^h ABBOTT LABORATORIES   (United States)

Author keywords

Combination drug therapy; HIV protease inhibitors; Lamivudine; Lymphoid tissue; Ritonavir; Tonsil; Zidovudine

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GENE MUTATION; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; LYMPHOID TISSUE; MALE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TONSIL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; LYMPHOID TISSUE; MALE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TONSIL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 6844252894     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199802000-00006     Document Type: Article

References (35)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Mathez P, Bagnarelli P, Gorin I, et al.: Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antiviral Ther 1997, ii:175-218.
4. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
5. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
6. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
7. Schmit JC, Ruiz L, Clotet B, et al.: Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10:995-999.
8. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
9. Bartlett JA, Benoit SL, Johnson VA, et al.: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:161-172.
10. Staszewski S, Loveday C, Picazo JJ, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:111-117.
11. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
12. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
13. Embretson J, Zupanolo M, Ribas JL, et al.: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362:359-362.
14. Pantaleo G, Graziosi C, Demarest JF, et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
15. Haase AT, Henry K, Zupancic M, et al.: Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996, 274:985-989.
16. Faust RA, Henry K, Dailey P, et al.: Outpatient biopsies of the palatine tonsil: access to lymphoid tissue for assessment of human immunodeficiency virus RNA titers. Otolaryngol Head Neck Surg 1996, 114:593-598.
17. Cohen OJ, Pantaleo G, Holodniy M, et al.: Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995, 92:6017-6021.
18. Cohen OJ, Pantaleo G, Holodniy M, et al.: Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J Infect Dis 1996, 173:849-856.
19. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O: Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. J Infect Dis 1996, 174:404-407.
20. Lafeuillade A, Tamalet C, Poggi C, Pellegrino P, Tourres C, Izopet J: Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes. AIDS 1997, 11:67-72.
21. Bürgisser P, Spertini F, Weyrich-Suter C, Pagani J-L, Meylan PRA: Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration. J Infect Dis 1997, 175:1202-1205.
22. Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N: Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS 1997, 11:895-901.
23. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
24. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, van der Noordaa J: A rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990, 28:495-503.
25. Kellam P, Boucher CA, Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
26. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
27. Markowitz M, Mo H, Kempf DJ, et al.: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995, 69:701-706.
28. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
29. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
30. Patterson BK, Till M, Otto P, et al.: Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science 1993, 260:976-979.
31. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
32. Cavert W, Notermans DW, Staskus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
33. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
34. Ho DD: Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
35. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.